Registry Study of Genetic Changes in Melanoma Patients in Taiwan Including Early, Locally Advanced, and Advanced Stages

What this Trial Is About

Cutaneous melanoma is the most aggressive form of skin cancer and is rare in Taiwan, with an incidence of about 1 in 100,000 people. This research focuses on acral lentiginous melanoma and mucosal melanoma, which are more common in Taiwan than in Caucasian populations and have distinct clinical and genetic features. These melanoma types in Asians often have higher recurrence rates after surgery, respond less to immunotherapy, and have shorter times without disease progression, leading to generally poor survival outcomes. The study observes patients with different stages of melanoma, including early-stage acral melanoma stage III, locally advanced acral melanoma stage III, resectable, advanced unresectable or metastatic melanoma stage IIIIV or recurrent, and those with advanced melanoma who have comprehensive genetic testing reports. Patients may provide tumor tissue samples for genetic analysis. The study tracks these groups to better understand the diseases progression and genetic alterations. Participants will be followed regularly for data collection, including tumor tissue analysis and medical history review. Researchers aim to evaluate how acral melanoma evolves over time in Taiwan. Patients are expected to have a life expectancy of more than three months and must be willing to provide tumor samples and comply with follow-up schedules. The study is observational and ongoing through December 2030.

The Registry Study of Genetic Alterations of Melanoma in Taiwan